Immunovant (IMVT) Competitors

Moderna (NASDAQ:MRNA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.

Is MRNA or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Moderna's return on equity of -28.74% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-110.04%	-28.74%	-21.83%
Immunovant	N/A	-77.94%	-69.82%

Do institutionals & insiders hold more shares of MRNA or IMVT?

75.3% of Moderna shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 11.0% of Moderna shares are held by insiders. Comparatively, 5.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer MRNA or IMVT?

Moderna received 83 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.65% of users gave Immunovant an outperform vote while only 53.62% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Moderna	Outperform Votes 215 53.62%	Underperform Votes 186 46.38%
Immunovant	Outperform Votes 132 77.65%	Underperform Votes 38 22.35%

Which has higher earnings and valuation, MRNA or IMVT?

Immunovant has lower revenue, but higher earnings than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$3.20B	3.45	-$3.56B	-$9.28	-3.08
Immunovant	N/A	N/A	-$259.34M	-$2.62	-6.16

Does the media prefer MRNA or IMVT?

In the previous week, Moderna had 18 more articles in the media than Immunovant. MarketBeat recorded 32 mentions for Moderna and 14 mentions for Immunovant. Moderna's average media sentiment score of 0.98 beat Immunovant's score of 0.88 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	18 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend MRNA or IMVT?

Moderna currently has a consensus price target of $58.70, indicating a potential upside of 105.68%. Immunovant has a consensus price target of $38.33, indicating a potential upside of 137.36%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04
Immunovant	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Which has more volatility and risk, MRNA or IMVT?

Moderna has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Summary

Moderna beats Immunovant on 10 of the 17 factors compared between the two stocks.